The pharmacotherapeutic management of gastroesophageal reflux disease (GERD)

Naga Rani K; Sunita K; Sudharani K; Salma Sulthana Sk; Pranathi P

doi:10.38022/ajhp.v2i2.51

K.Naga Rani Department of Pharmacy Practice, Hindu College of Pharmacy, Amaravathi Road, Guntur (AP), India.
drkondaravikumar@gmail.com
K.Sunita Department of Pharmacy Practice, Hindu College of Pharmacy, Amaravathi Road, Guntur (AP), India.
K.Sudharani Department of Pharmacy Practice, Hindu College of Pharmacy, Amaravathi Road, Guntur (AP), India.
Sk.Salma Sulthana Department of Pharmacy Practice, Hindu College of Pharmacy, Amaravathi Road, Guntur (AP), India.
P.Pranathi Department of Pharmacy Practice, Hindu College of Pharmacy, Amaravathi Road, Guntur (AP), India.

DOI https://doi.org/10.38022/ajhp.v2i2.51

Abstract

Medical therapy of gastroesophageal reflux disease (GERD) is based on the use of proton pump inhibitors (PPIs) as first choice treatment. Despite their effectiveness, about 20-30% of patients report an inadequate response and alternative drugs are required. Areas covered: This review provides an overview of current pharmacotherapy for treating GERD by showing the results of PPIs, reflux inhibitors, antidepressants and mucosa protective medications. Expert opinion: Medical therapy of GERD does not definitely cure the disease, because even PPIs are not able to change the key factors responsible for it. However, they remain the mainstay of medical treatment, allowing us to alleviate symptoms, heal esophagitis and prevent complications in the majority of cases. Nevertheless, many patients do not respond, because acid does not play any pathogenetic role. Prokinetics and reflux inhibitors have the potential to control motor abnormalities, but the results of clinical trials are inconsistent. Antidepressant drugs are effective in specific subgroups of NERD patients with visceral hypersensitivity, but larger, controlled clinical studies are necessary. Protective drugs or medical devices have been recently adopted to reinforce mucosal resistance and preliminary trials have confirmed their efficacy either combined with or as add-on medication to PPIs in refractory patients.

Keywords: Gastroesophageal reflux disease, erosive esophagitis, potassium-competitive acid blocker, proton-pump inhibitor, refractory gastroesophageal reflux disease

Downloads

Download data is not yet available.

References

1. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900–1920. doi:10.1111/j.1572-0241.2006.00630.x
2. Dent J, El-Serag HB, Wallander MA, et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54:710–717. doi:10.1136/gut.2004.051821.
3. Pandolfino JE, El-Serag HB, Zhang Q, et al. Obesity: a challenge to esophagogastric junction integrity. Gastroenterology. 2006;130:639–649. doi:10.1053/j.gastro.2005.12.016.
4. Savarino E, Zentilin P, Marabotto E, et al. Overweight is a risk factor for both erosive and non-erosive reflux disease. Dig Liver Dis. 2011;43:940–945. doi:10.1016/j.dld.2011.07.014.
5. Herregods TV, Bredenoord AJ, Smout AJ. Pathophysiology of gastroesophageal reflux disease: new understanding in a new era. Neurogastroenterol Motil. 2015;27:1202–1213. doi:10.1111/nmo.12611
6. Savarino E, de Bortoli N, De Cassan C, et al. The natural history of gastro-esophageal reflux disease: a comprehensive review. Dis Esophagus. 2017;30:1–9. . doi:10.1111/dote.12511.
7. Savarino V, Marabotto E, Zentilin P, et al. Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease. Expert Rev Clin Pharmacol. 2020;13:437–449. doi:10.1080/17512433.2020.1752664.
8. Pouderoux P, Verdier E, Kahrilas PJ. Patterns of esophageal inhibition during swallowing, pharyngeal stimulation, and transient LES relaxation. Lower esophageal sphincter. Am J Physiol Gastrointest Liver Physiol. 2003;284:G242–G247. doi:10.1152/ajpgi.00301.2002.
9. Savarino E, Mei F, Parodi A, et al. Gastrointestinal motility disorder assessment in systemic sclerosis. Rheumatology. 2013;52:1095–1100. doi:10.1093/rheumatology/kes429.
10. Tolone S, Savarino E, Zaninotto G, et al. High-resolution manometry is superior to endoscopy and radiology in assessing and grading sliding hiatal hernia: a comparison with surgical in vivo evaluation. United European Gastroenterol J. 2018;6:981–989. doi:10.1177/2050640618769160.
11. Savarino E, Bredenoord AJ, Fox M, et al. International working group for disorders of gastrointestinal motility and function. Expert consensus document: advances in the physiological assessment and diagnosis of GERD. Nat Rev Gastroenterol Hepatol. 2017;14:665–676. . doi:10.1038/nrgastro.2017.130.
12. Frazzoni M, de Bortoli N, Frazzoni L, et al. Impedance-pH monitoring for diagnosis of reflux disease: new perspectives. Dig Dis Sci. 2017;62:1881–1889. doi:10.1007/s10620-017-4625-8.
13. Nobile S, Meneghin F, Marchionni P, et al. Response to therapy among neonates with gastro-esophageal reflux is associated with esophageal clearance. Early Hum Dev. 2021;152:105248. doi:10.1016/j.earlhumdev.2020.105248.
14. McCallum RW, Berkowitz DM, Lerner E. Gastric emptying in patients with gastroesophageal reflux. Gastroenterology. 1981;80:285–291. doi:10.1016/0016-5085(81)90716-2.